Elamipretide the Mitochondrial Peptide

Mitochondrial health is a cornerstone of performance, energy, and longevity, yet for years, our approach to it has been mostly reactive. That might be changing. Elamipretide (Forzinity) is the first therapy to move beyond symptom management and step inside the cell's power stations to attempt structural repair. Approved for the ultra-rare Barth syndrome, this pioneering mitochondrial peptide signals a major conceptual shift: that the energy machinery of our cells may not be an inevitable victim of aging, but a modifiable system ready for sophisticated intervention. Dr Andrew Crockett looks at how it works, what the science says, and what this development means for the future of healthspan.